1-14 of 14
Shruti Kapoor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

With up to 8 Years of Therapy, Asciminib (ASC) Monotherapy Demonstrated Continued Favorable Efficacy, Safety, and Tolerability in Patients (Pts) with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) without the T315I Mutation: Final Results from the Phase 1 X2101 Study

Andreas Hochhaus, Dong-Wook Kim, Jorge Cortes, Koji Sasaki, Michael Mauro, Timothy P Hughes, Massimo Breccia, Moshe Talpaz, Hironobu Minami, Yeow Tee Goh, Daniel J. DeAngelo, Fabian Lang, Michael C. Heinrich, Valle Gomez G De Soria, Philipp le Coutre, Gessami Sanchez-Olle, Jomy Jose, Nathalie Pognan, Shruti Kapoor, Delphine Rea
Journal: Blood
Blood (2023) 142 (Supplement 1): 450.
https://doi.org/10.1182/blood-2023-187322
Published: 2023
Journal Articles

ASC4START and ASC4FIRST: Two Ongoing Phase 3 Trials Investigating Asciminib Monotherapy As First-Line Therapy Versus Tyrosine Kinase Inhibitors in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Andreas Hochhaus, Jorge Cortes, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Susanne Saussele, Francois Mahon, Tim H. Brümmendorf, Shruti Kapoor, Tracey McCulloch, Peter Schuld, Timothy P Hughes
Journal: Blood
Blood (2023) 142 (Supplement 1): 6388.
https://doi.org/10.1182/blood-2023-186773
Published: 2023
Journal Articles

ASC4KIDS: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Chronic Myeloid Leukemia in the Chronic Phase

Nobuko Hijiya, Shruti Kapoor, Matthias Hoch, Laurence Descamps, Vishal Dhamal, Ana Paula Torres Cardoso
Journal: Blood
Blood (2023) 142 (Supplement 1): 6387.
https://doi.org/10.1182/blood-2023-185535
Published: 2023
Journal Articles

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Timothy P Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Torres Cardoso, Jomy Jose, Monali Sura, Jorge Cortes
Journal: Blood
Blood (2023) 142 (Supplement 1): 866.
https://doi.org/10.1182/blood-2023-182100
Published: 2023
Journal Articles

Sustained Efficacy and Safety with Asciminib (ASC) after Almost 4 Years of Median Follow-up from Ascembl, a Phase 3 Study of ASC Vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): An End of Study Treatment (EOS Tx) Update, Including Results from Switch Population

Michael Mauro, Yosuke Minami, Andreas Hochhaus, Elza Lomaia, Sergei Voloshin, Anna Turkina, Dong-Wook Kim, Jane F Apperley, Jorge Cortes, Andre N.R. Abdo, Laura Maria Fogliatto, Dennis Dong Hwan Kim, Philipp le Coutre, Susanne Saussele, Mario Annunziata, Timothy P Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín García Gutiérrez, Koji Sasaki, Carla Maria Boquimpani De Moura Freitas, Shruti Kapoor, Noemi Espurz, Vishal Dhamal, Delphine Rea
Journal: Blood
Blood (2023) 142 (Supplement 1): 4536.
https://doi.org/10.1182/blood-2023-186854
Published: 2023
Journal Articles

ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Timothy Hughes, Jorge E. Cortes, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Nicholas Ramscar, Shruti Kapoor, Sophie Ifrah, Andreas Hochhaus
Journal: Blood
Blood (2022) 140 (Supplement 1): 6767–6768.
https://doi.org/10.1182/blood-2022-162249
Published: 2022
Journal Articles

Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study

Timothy Hughes, Delphine Rea, Carla Boquimpani, Yosuke Minami, Michael Mauro, Jorge E. Cortes, Jane F. Apperley, Valentín García Gutiérrez, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Yifan Zhang, Andreas Hochhaus
Journal: Blood
Blood (2022) 140 (Supplement 1): 6757–6759.
https://doi.org/10.1182/blood-2022-169110
Published: 2022
Journal Articles

ASC4KIDS: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Chronic Myeloid Leukemia in Chronic Phase

Nobuko Hijiya, Shruti Kapoor, Matthias Hoch, Laurence Descamps, Kohinoor Dasgupta, Nicholas Ramscar
Journal: Blood
Blood (2022) 140 (Supplement 1): 12204–12205.
https://doi.org/10.1182/blood-2022-162451
Published: 2022
Journal Articles

Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML-CP) with and without the T315I Mutation

Francois Pierre Combes, Ying Fei Li, Sherwin K.B. Sy, Sebastien Lorenzo, Kohinoor Dasgupta, Shruti Kapoor, Matthias Hoch, Yu-Yun Ho
Journal: Blood
Blood (2022) 140 (Supplement 1): 6791–6792.
https://doi.org/10.1182/blood-2022-163078
Published: 2022
Journal Articles

Trial in Progress: A Multicenter, Open-Label, Phase Ib/II Study to Determine the Dose and Safety of Asciminib in Pediatric Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Treated with ≥1 Prior Tyrosine Kinase Inhibitor

Nobuko Hijiya, Shruti Kapoor, Laurence Descamps, Mohamed Amine Bayar, Nicholas Ramscar
Journal: Blood
Blood (2021) 138 (Supplement 1): 2561.
https://doi.org/10.1182/blood-2021-151198
Published: 2021
Journal Articles

Trial in Progress: A Multicenter, Open Label, Randomized, Phase III Study of Asciminib (80 mg Once Daily) Vs Investigator-Selected TKI in Newly Diagnosed Adult Patients with Chronic Myeloid Leukemia in Chronic Phase

Jorge E. Cortes, Andreas Hochhaus, Naoto Takahashi, Richard A. Larson, Ghayas C. Issa, Felice Bombaci, Nicholas Ramscar, Shruti Kapoor, Sophie Ifrah, Timothy P. Hughes
Journal: Blood
Blood (2021) 138 (Supplement 1): 1478.
https://doi.org/10.1182/blood-2021-151239
Published: 2021
Journal Articles

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

Michael J. Mauro, Yosuke Minami, Delphine Rea, Andreas Hochhaus, Elza Lomaia, Sergey Voloshin, Anna G. Turkina, Dong-Wook Kim, Jane F Apperley, Jorge E. Cortes, Andre N.R. Abdo, Laura Fogliatto, Dennis Dong Hwan Kim, Philipp D le Coutre, Susanne Saussele, Mario Annunziata, Timothy P. Hughes, Naeem A. Chaudhri, Lynette C.Y. Chee, Valentín Garcia Gutierrez, Koji Sasaki, Shruti Kapoor, Alex Allepuz, Sarah Quenet, Véronique Bédoucha, Carla Boquimpani
Journal: Blood
Blood (2021) 138 (Supplement 1): 310.
https://doi.org/10.1182/blood-2021-152561
Published: 2021
Journal Articles

Comprehensive Analysis of Immunophenotype and Transcriptome in Indian T-Acute Lymphoblastic Leukemia - a Prospective Study

Anita Chopra, MD DM, Deepak Verma, PhD, Shruti Kapoor, PhD, Jay Singh, MSc, Jayanth Kumar Kumar Palanichamy, MDMBBS, Raja Pramanik, MD DM, Atul Sharma, MD DM, Sameer Bakhshi, MD, Ranjit Kumar Sahoo, MDDM, Vinod Scaria, MBBS PhD, Lalit Kumar, MDDM, Sridhar Sivasubbu, PhD, Rajive Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1467.
https://doi.org/10.1182/blood-2019-127980
Published: 2019
Journal Articles

Randomized, Open-Label, Multicenter, Phase 2 Study of Asciminib (ABL001) As an Add-on to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Have Not Achieved a Deep Molecular Response with Frontline Imatinib

Giuseppe Saglio, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Jan Geissler, Shruti Kapoor, Anne-Sophie Longin, Ayon Mukherjee, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5910.
https://doi.org/10.1182/blood-2019-124702
Published: 2019